A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

Completed · Phase 3

Conditions studied: Rheumatoid Arthritis

In brief

An open ended study in which patients who completed the preceding double-blind study NCT00160602 are given Certolizumab Pegol and assessed for signs and symptoms of Rheumatoid Arthritis.

Key facts

Study ID

NCT00160641

Run by

UCB Pharma

People needed

567

Starts

2005-11-01

Expected to finish

2012-02-01

Last updated by the study team

2020-03-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have either failed to achieve an American College of Rheumatology 20 % (ACR20) response at Weeks 12 and 14 in C87050 [NCT00160602], or must have completed the entire Week 24 assessment of C87050 [NCT00160602] trial.

You may not qualify if…

• A diagnosis of any other inflammatory Arthritis (e.g. Psoriatic Arthritis or Ankylosing Spondylitis)
• A secondary, non-inflammatory type of Arthritis (e.g. Osteoarthritis or Fibromyalgia) that in the Investigator's opinion is symptomatic enough to interfere with evaluation of the effect of CDP870 on the patient's primary diagnosis of Rheumatoid Arthritis (RA)
• Any concomitant biological therapy
• Any experimental therapy, within or outside a clinical

Where it is running

• 185 — Pasadena, California, United States
• 170 — Santa Maria, California, United States
• 194 — Whittier, California, United States
• 176 — Naples, Florida, United States
• 186 — Palm Harbor, Florida, United States
• 188 — Kansas City, Missouri, United States
• 182 — St Louis, Missouri, United States
• 178 — Stratford, New Jersey, United States
• 192 — Amarillo, Texas, United States
• 173 — Austin, Texas, United States
• 175 — San Antonio, Texas, United States
• 303 — Pleven, Bulgaria
• 302 — Sofia, Bulgaria
• 500 — Rijeka, Croatia
• 600 — Brno, Czechia
• 603 — Hlučín, Czechia
• 605 — Prague, Czechia
• 606 — Prague, Czechia
• 604 — Sokolov, Czechia
• 602 — Uherské Hradiště, Czechia
• 607 — Zlín, Czechia
• 700 — Tallinn, Estonia
• 802 — Afula, Israel
• 805 — Ashkelon, Israel
• 172 — Palm Desert, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.